Abstract 2438
Background
This study was carried out as descriptive and cross-sectional in order to determine the compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) levels of the nurses working in oncology-hematology and the factors affecting them.
Methods
The sample of the study consisted of 125 oncology-hematology nurses working in two private hospitals, one university hospital. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Descriptive statistics, numbers and percentages and X±SD were used according to the data type. The factors affecting dependent variables were tested with multilevel models (MLM).
Results
In the study, 89.6% (n: 112) of the nurses were women, 80% (n: 100) were unmarried, 70.4% (n: 88) have Bachelor’s degree, mean age was 26.82±5.32, and the average years of total working at oncology was 2.78±2.35, the average weekly working hours was 49.75 ± 4.26, 65.6% (n: 82) said that the social support is not enough. When the mean scores of the nurses were examined, the CF was 13.53±7.25, BO was 20.14±6.77, CS was 37.92±7.40, PS was 32.00±3.44, PR was 135.43±17.29. There was a statistically significant effect of weekly working hour on BO, CS and PS (p < 0.05). 1 hour more work per week leads to a 0.5 point decrease in CS mean scores, 0,45 points increase in BO mean scores and 0,18 points increase in PS mean scores. When we compare the nurses their answers to social support question, nurses who said that social support is insufficient, have 3.1 points higher CF, 2.6 points lower CS, and 8.8 points lower PR mean scores (p < 0.05).
Conclusions
In this study, it was found that nurses had moderate levels of CF, BO and CS. While having social support positively affected the dependent variables, it was found that the increase in the weekly working hours negatively affected. These results are a key finding for the managers of the institutions especially in providing the healthy working life of nurses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract